CD47 and neoplasm: For example, breast tumor-bearing mice benefitted from the combinatorial treatment with the mAb trastuzumab directed against the human epidermal receptor 2 (HER2) and the blockade of the SIRPα/CD47 checkpoint interaction that increased the killing activity of neutrophils towards antibody-opsonized cancer cells and led to tumor shrinkage caused by the antibody-dependent cell cytotoxicity (ADCC) (111) (Figure 1C).